|
|
News Breaks
|
November 16, 2009
|
| 09:06 EDT |  | HEPH |
| theflyonthewall.com: | Hollis-Eden reports preliminary results of Phase I/II clinical trial of Apopton | | Hollis-Eden Pharmaceuticals, Inc. reported preliminary results of its ongoing Phase I/II clinical trial with Apoptone, or HE3235, for hormone-resistant prostate cancer, also called castrate-resistant prostate cancer, or CRPC. The interim results of the Phase I/II study, which is being conducted with participating member sites of the Prostate Cancer Clinical Trial Consortium, or PCCTC, demonstrated that 47% of subjects who were radiographically evaluable for response had stable disease. With the assessment of progression every 56 days, the median time to progression was 107 days. Forty-three percent of the biochemically evaluable subjects experienced a drop in PSA during treatment, with 33% equal to or greater than a 50% decline. The data was presented at the Molecular Targets and Cancer Therapeutics Conference, which is co-sponsored by the AACR, NCI and EORTC. :theflyonthewall.com |
|
|
News For HEPH From The Last 14 Days Check below for free stories on HEPH the last two weeks.
| Sign up for a free trial to see the rest of the stories you've been missing. |
There are no results for these search parameters.
|
|
|
|
